Author

Huafang Mao

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

CCT2 defines a highly cisplatin-resistant and poor-prognosis subtype of lung adenocarcinoma

The present findings identified CCT2 as a key mediator of cisplatin resistance in LUAD and provided potential therapeutic strategies to overcome chemotherapy resistance.

Huafang Mao, Chao Su, Xiao-Liang Han et al. · Oncology Letters · 0 citations